Book a Meeting

Non-Fucosylated Anti-Human TIGIT (14D7) Therapeutic Antibody (CAT#: BioBet-1730ZP) Datasheet

Target
TIGIT
Isotype
IgG
Description
Non-Fucosylated Anti-Human TIGIT (14D7) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TIGIT antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TIGIT
Full Name
T cell immunoreceptor with Ig and ITIM domains
Background
TIGIT (also called T cell immunoreceptor with Ig and ITIM domains) is an immune receptor present on some T cells and Natural Killer Cells (NK). It is also identified as WUCAM and Vstm3. TIGIT could bind to CD155 (PVR) on dendritic cells (DCs), macrophages, etc. with high affinity, and also to CD112 (PVRL2) with lower affinity.

Research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
14D7
Host
Murine
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Related Products

BetterBet™ Anti-TIGIT Recycling Antibody (CAT#: AES-0622-ZP115)
ADCC-Enhanced Anti-Human TIGIT (Tiragolumab) Antibody (CAT#: BioBet-CB-093LX)
Non-Fucosylated Anti-Human TIGIT (26B10) Therapeutic Antibody (CAT#: BioBet-1731ZP)
BetterBet™ Anti-TIGIT On-Target Antibody (CAT#: AES-0622-ZP771)
BetterBet™ Anti-TIGIT Half-Life Extended Antibody (CAT#: AES-0622-ZP1099)
BetterBet™ Anti-TIGIT FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP443)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.